RxDoctor Payments Data

James Beckmen, DO

Family Medicine · Solvang, CANPI 1205867561

Payments from drug & device makers

$690in general payments, 2019–2025

Across 45 payments — averaging $15.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$114
  • Supernus Pharmaceuticals, Inc.$114
  • AbbVie$113
  • Boehringer Ingelheim$67
  • Lilly USA, LLC$58
  • Therapeuticsmd, Inc.$25
  • plus $200 from 13 others

What the payments were for

  • Food & beverage$690100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$690 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$199,724
Medicare patients
541
Services billed
3,883

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban182$169,374
OzempicSemaglutide92$95,973
JardianceEmpagliflozin99$90,829
TrulicityDulaglutide55$74,095
XareltoRivaroxaban47$51,062
JanuviaSitagliptin Phosphate44$35,755
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$27,424
MyrbetriqMirabegron33$16,143
MounjaroTirzepatide14$15,138
GemtesaVibegron14$14,536
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen469$11,841
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$11,662
BelsomraSuvorexant21$8,898
CreonLipase/Protease/Amylase13$8,596
Advair HfaFluticasone Propion/Salmeterol23$8,468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$114$169,374182 claims
Boehringer IngelheimJardiance$67$90,82999 claims
Lilly USA, LLCTrulicity, Mounjaro$58$89,23469 claims
Johnson & JohnsonXarelto$15$51,06247 claims
GSKTrelegy Ellipta, Anoro Ellipta$13$39,08655 claims
AbbVieCreon, Namzaric, Synthroid$113$18,45774 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Solvang

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →